Correction to: Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study (Neurotherapeutics, (2021), 18, 2, (1127-1136), 10.1007/s13311-020-01004-3)

Stacy A. Rudnicki, Jinsy A. Andrews, Tina Duong, Bettina M. Cockroft, Fady I. Malik, Lisa Meng, Jenny Wei, Andrew A. Wolff, Angela Genge, Nicholas E. Johnson, Carolina Tesi-Rocha, Anne M. Connolly, Basil T. Darras, Kevin Felice, Richard S. Finkel, Perry B. Shieh, Jean K. Mah, Jeffrey Statland, Craig Campbell, Ali A. HabibNancy L. Kuntz, Maryam Oskoui, John W. Day*

*Corresponding author for this work

Research output: Contribution to journalComment/debatepeer-review

Abstract

This article has been updated to add the author Richard S. Finkel. The original article has been corrected.

Original languageEnglish (US)
Pages (from-to)2130
Number of pages1
JournalNeurotherapeutics
Volume18
Issue number3
DOIs
StatePublished - Jul 2021
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Correction to: Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study (Neurotherapeutics, (2021), 18, 2, (1127-1136), 10.1007/s13311-020-01004-3)'. Together they form a unique fingerprint.

Cite this